AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7962341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg) plus Arginine (0.5 g/kg)
Number of subjects: 29
Study 2887418 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (Imdur) 60mg once daily
Number of subjects: 70
Study 2887418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29160000 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous keratin and fibroblast
Number of subjects: 30
Study 29160000 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 30
Study 27073242 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 292
Study 27073242 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic obliteration
Number of subjects: 292
Study 27073242 — intervention group
Group type: COMPARATOR
Intervention: Before SRS
Number of subjects: 292
Study 24076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily coffee consumption
Number of subjects: 240
Study 24076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption at age 18
Number of subjects: 240
Study 24076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever daily smoking
Number of subjects: 240
Study 24076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis for ever daily smokers
Number of subjects: 240
Study 24076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception use in females
Number of subjects: 240
Study 24076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of children before PSC diagnosis
Number of subjects: 240
Study 23327226 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP35)
Number of subjects: 60
Study 23327226 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% hydrogen peroxide (HP20)
Number of subjects: 60
Study 20722756 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments 30, 0.02 taper
Number of subjects: 44
Study 20722756 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments 35, 0.02 taper
Number of subjects: 44
Study 20722756 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments 40, 0.02 taper
Number of subjects: 44
Study 20722756 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments 45, 0.02 taper
Number of subjects: 44
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Cypher stent (279 patients)
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent (318 patients)
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Endeavor stent (239 patients)
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Cypher stent
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Three studies with primary surrogate endpoint (DIABETES, SCORPIUS, ISAR-DIABETES)
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of Cypher patients (627 patients)
Number of subjects: 34677
Study 18568314 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of Taxus patients (814 patients)
Number of subjects: 34677
Study 16608136 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based strength training (n=34)
Number of subjects: 68
Study 16608136 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=34)
Number of subjects: 68
Study 12702114 — intervention group
Group type: EXPERIMENTAL
Intervention: BDX + collagen membrane
Number of subjects: 28
Study 12702114 — intervention group
Group type: COMPARATOR
Intervention: Access flap surgery
Number of subjects: 28
Study 11731754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg i.v.)
Number of subjects: 51
Study 11731754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg i.v.)
Number of subjects: 51
Study 11731754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg i.v.) followed by Ketorolac (30 mg)
Number of subjects: 51
Study 11731754 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 51
Study 11731754 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (K, T, KT)
Number of subjects: 51
Study 9040549 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 8 (iron approximately 143 mumol/L or 8 mg/L)
Number of subjects: 52
Study 9040549 — intervention group
Group type: EXPERIMENTAL
Intervention: Similac with Iron (iron approximately 215 mumol/L or 12 mg/L)
Number of subjects: 52
Study 7730891 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2889255 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once daily at bedtime for 4 weeks
Number of subjects: 234
Study 2889255 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at bedtime for 4 weeks
Number of subjects: 234
Study 29560939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg orally per day
Number of subjects: 40
Study 29560939 — intervention group
Group type: COMPARATOR
Intervention: Previous NSAID therapy (control)
Number of subjects: 40
Study 28161554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d
Number of subjects: 210
Study 28161554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 26327301 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (11 mg/kg administered intravenously every 3 weeks, or every 6 weeks at investigator's discretion)
Number of subjects: 19
Study 26327301 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 19
Study 23204550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg i.v. infusion given four times over 10 days
Number of subjects: 82
Study 23204550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 23204550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (open label after 50 days)
Number of subjects: 82
Study 21753156 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2334737 monotherapy (40 mg)
Number of subjects: 65
Study 21753156 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2334737 in combination with erlotinib (100 mg)
Number of subjects: 65
Study 21753156 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2334737 monotherapy
Number of subjects: 65
Study 21753156 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2334737
Number of subjects: 65
Study 21753156 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2334737 drug formulations
Number of subjects: 65
Study 19192477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular second-generation antipsychotics (SGAs)
Number of subjects: 3425
Study 19192477 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol alone
Number of subjects: 3425
Study 19192477 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol plus promethazine
Number of subjects: 3425
Study 16607104 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 30
Study 16607104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16607104 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol producers (n = 15)
Number of subjects: 30
Study 16607104 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-equol producers (n = 15)
Number of subjects: 30
Study 14664280 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 11688
Study 14664280 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 11688
Study 10856868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral extracorporeal circulation
Number of subjects: 18
Study 10856868 — intervention group
Group type: COMPARATOR
Intervention: Routine extracorporeal circulation
Number of subjects: 18
Study 9367289 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude hypoxia (4350m above sea level) for four days
Number of subjects: 10
Study 31794507 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unilateral open‐door laminoplasty with posterior muscle‐ligament complex preservation
Number of subjects: 63
Study 28815614 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 0
Study 28815614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25738952 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Youth (FOY) media
Number of subjects: 1613
Study 25738952 — intervention group
Group type: COMPARATOR
Intervention: Promoting Health Among Teens (PHAT) media
Number of subjects: 1613
Study 25738952 — intervention group
Group type: COMPARATOR
Intervention: General health curriculum (PHAT non-media)
Number of subjects: 1613
Study 25738952 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-tailored media intervention
Number of subjects: 1613
Study 25738952 — intervention group
Group type: COMPARATOR
Intervention: Focus on Youth (FOY) non-media
Number of subjects: 1613
Study 23340117 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS to contralateral dPMC
Number of subjects: 12
Study 23340117 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS protocol
Number of subjects: 12
Study 19721433 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 738
Study 19721433 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 738
Study 19721433 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 738
Study 19721433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 738
Study 19721433 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 738
Study 18664984 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (CIP) for 6-8 weeks
Number of subjects: 97
Study 18664984 — intervention group
Group type: COMPARATOR
Intervention: Topical framycetin-gramicidin-dexamethasone (FGD) for 6-8 weeks
Number of subjects: 97
Study 15976212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 152
Study 15976212 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 152
Study 15976212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 15976212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g and Propacetamol 2 g
Number of subjects: 152
Study 14692430 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray
Number of subjects: 20
Study 14692430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10668523 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study 10668523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10668523 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 0
Study 8765824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) solution
Number of subjects: 43
Study 8765824 — intervention group
Group type: COMPARATOR
Intervention: Topical steroids (beclomethasone dipropionate (BD) ointment)
Number of subjects: 43
Study 1913269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragments of Pool 2 (fSRW)
Number of subjects: 3
Study 1913269 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ragweed preparation (Pool 2)
Number of subjects: 3
Study 1913269 — intervention group
Group type: COMPARATOR
Intervention: Histamine (placebo)
Number of subjects: 3
Study 6807934 — intervention group
Group type: COMPARATOR
Intervention: Detergent wash
Number of subjects: 119
Study 6807934 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-phenate solution (1:16 dilution, 10 minute immersion)
Number of subjects: 119
Study 6807934 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 119
Study 30880807 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured DVD education
Number of subjects: 0
Study 30880807 — intervention group
Group type: COMPARATOR
Intervention: Standard one‐on‐one education
Number of subjects: 0
Study 28976989 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day for 12 weeks)
Number of subjects: 88
Study 28976989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27019001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg and Everolimus 10 mg, both once daily for 4 weeks (1 cycle)
Number of subjects: 24
Study 24285427 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vitamin K1 orally thrice weekly
Number of subjects: 348
Study 24285427 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 348
Study 22323353 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 309
Study 22323353 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 309
Study 22323353 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Diet
Number of subjects: 309
Study 22323353 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Lifestyle)
Number of subjects: 309
Study 18677491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming arm group (AA)
Number of subjects: 20
Study 18677491 — intervention group
Group type: COMPARATOR
Intervention: Free hand (FH) group
Number of subjects: 20
Study 17552400 — intervention group
Group type: EXPERIMENTAL
Intervention: High compression plus amelogenin
Number of subjects: 83
Study 17552400 — intervention group
Group type: COMPARATOR
Intervention: High compression therapy alone
Number of subjects: 83
Study 15526982 — intervention group
Group type: EXPERIMENTAL
Intervention: triptorelin (GnRH agonist)
Number of subjects: 46
Study 15526982 — intervention group
Group type: COMPARATOR
Intervention: ganirelix (GnRH antagonist)
Number of subjects: 46
Study 11200962 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28
Study 11200962 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 28
Study 9591441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream or ointment applied to lesional skin twice daily for 7-19 days
Number of subjects: 40
Study 7814359 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment (3-6 months)
Number of subjects: 0
Study 7814359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment (6-24 months)
Number of subjects: 0
Study 3336995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0
Study 3336995 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 31449956 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy combined with DCB angioplasty (n = 45)
Number of subjects: 94
Study 31449956 — intervention group
Group type: COMPARATOR
Intervention: DCB angioplasty alone (n = 49)
Number of subjects: 94
Study 31436146 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gown with increased skin coverage at the hands and wrists
Number of subjects: 0
Study 31436146 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on donning and doffing technique
Number of subjects: 0
Study 31436146 — intervention group
Group type: COMPARATOR
Intervention: Standard gown
Number of subjects: 0
Study 28498853 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR-901 (1 mg)
Number of subjects: 16
Study 28498853 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 16
Study 26071347 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of HPV-16/18 vaccine
Number of subjects: 24055
Study 26071347 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV-16/18 vaccine
Number of subjects: 24055
Study 26071347 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of HPV-16/18 vaccine
Number of subjects: 24055
Study 26071347 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV-16/18 vaccine (second dose at 1 month)
Number of subjects: 24055
Study 26071347 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV-16/18 vaccine (second dose at 6 months)
Number of subjects: 24055
Study 23877287 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Method 1
Number of subjects: 0
Study 23877287 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Method 2
Number of subjects: 0
Study 22162639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy-ER (5 mg)
Number of subjects: 103
Study 22162639 — intervention group
Group type: COMPARATOR
Intervention: Oxy-CRF (5 mg)
Number of subjects: 103
Study 22162639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy-ER (40 mg)
Number of subjects: 103
Study 22162639 — intervention group
Group type: COMPARATOR
Intervention: Oxy-CRF (40 mg)
Number of subjects: 103
Study 22162639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy-ER (40 mg) after high-fat breakfast
Number of subjects: 103
Study 22162639 — intervention group
Group type: COMPARATOR
Intervention: Oxy-CRF (40 mg) after high-fat breakfast
Number of subjects: 103
Study 22162639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy-ER
Number of subjects: 103
Study 22162639 — intervention group
Group type: COMPARATOR
Intervention: Oxy-CRF
Number of subjects: 103
Study 19485429 — intervention group
Group type: COMPARATOR
Intervention: peginterferon-alpha-2b plus ribavirin for 48 weeks (PEG + R)
Number of subjects: 0
Study 19485429 — intervention group
Group type: COMPARATOR
Intervention: peginterferon-alpha-2b plus ribavirin according to German guidelines (GUIDE)
Number of subjects: 0
Study 19485429 — intervention group
Group type: COMPARATOR
Intervention: interferon-alpha-2b plus ribavirin for 48 weeks (IFN + R)
Number of subjects: 0
Study 19485429 — intervention group
Group type: COMPARATOR
Intervention: GUIDE
Number of subjects: 0
Study 19485429 — intervention group
Group type: COMPARATOR
Intervention: PEG + R
Number of subjects: 0
Study 16826006 — intervention group
Group type: EXPERIMENTAL
Intervention: Macro discectomy
Number of subjects: 119
Study 16826006 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 119
Study 16826006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 119
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg HFA‐BDP
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg HFA‐BDP
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg HFA‐BDP after ingestion of charcoal
Number of subjects: 14
Study 12567387 — intervention group
Group type: COMPARATOR
Intervention: 400 microg CFC‐BDP
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA treatment
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal absorption of BDP
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐BMP metabolism
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state volume of distribution of 17‐BMP
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal half-life after inhalations
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration of BDP
Number of subjects: 14
Study 12567387 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA Autohaler vs CFC-pMDI
Number of subjects: 14
Study 10833680 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation
Number of subjects: 67
Study 10833680 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 67
Study 10833680 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 67
Study 10833680 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 67
Study 8710419 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment with levamisole every 4 months
Number of subjects: 0
Study 8710419 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment with levamisole at two 6-monthly intervals
Number of subjects: 0
Study 8710419 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment with levamisole once in 1 year
Number of subjects: 0
Study 8710419 — intervention group
Group type: COMPARATOR
Intervention: Untreated children (aged 0-4 years)
Number of subjects: 0
Study 8710419 — intervention group
Group type: COMPARATOR
Intervention: Untreated adults
Number of subjects: 0
Study 2000046 — intervention group
Group type: EXPERIMENTAL
Intervention: E + C 20 mg/200 mg
Number of subjects: 6
Study 2000046 — intervention group
Group type: EXPERIMENTAL
Intervention: E + C 10 mg/200 mg
Number of subjects: 6
Study 2000046 — intervention group
Group type: EXPERIMENTAL
Intervention: E + C 20 mg/100 mg
Number of subjects: 6
Study 2000046 — intervention group
Group type: EXPERIMENTAL
Intervention: E + C 10 mg/200 mg and E + C 20 mg/100 mg
Number of subjects: 6
Study 2000046 — intervention group
Group type: EXPERIMENTAL
Intervention: All combinations
Number of subjects: 6
Study 6393621 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg molsidomine
Number of subjects: 12
Study 6393621 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg molsidomine
Number of subjects: 12
Study 6393621 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg and 6 mg molsidomine
Number of subjects: 12
Study 6393621 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg molsidomine administered 5-6 times daily or 4-6 mg applied 4-5 times daily
Number of subjects: 12
Study 31404020 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound + ERCP with minor papilla endoscopic sphincterotomy (miES)
Number of subjects: 234
Study 31404020 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ultrasound + sham
Number of subjects: 234
Study 30816013 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with ischaemic cardiomyopathy (ICM)
Number of subjects: 2293
Study 30816013 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with non-ischaemic cardiomyopathy (NICM)
Number of subjects: 2293
Study 28500087 — intervention group
Group type: EXPERIMENTAL
Intervention: MACS decision rule
Number of subjects: 138